BEAM Beam Therapeutics Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BEAM Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$31.56
Analyst Target
$45.47
+44.1%
Upside
52W High
$36.44
52W Low
$13.53
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and profitability concerns. Despite a strong analyst recommendation of 'strong_buy' and a target price implying 44% upside, the company exhibits negative gross and operating margins, deteriorating revenue growth, and deeply negative returns on equity and assets. Insider selling activity totaling $3.19M over the past six months contradicts the bullish analyst sentiment, while valuation multiples like a Price/Sales ratio of 57.50 are extremely stretched relative to fundamentals. Although the current ratio is strong at 6.02, suggesting near-term liquidity safety, the lack of Altman Z-Score and persistent unprofitability elevate long-term sustainability risks.
Key Strengths
Exceptionally strong liquidity position with a current ratio of 6.02 and quick ratio of 5.89, providing runway for R&D and operations
Low debt burden with a Debt/Equity ratio of 0.16, well below sector average of 2.71, reducing financial risk
Analyst consensus is strongly bullish with a 'strong_buy' rating from 15 analysts and a mean target price of $45.47
Recent price momentum is positive, with +45.3% return over the last 6 months and +20.1% over the past year
Peer group context shows BEAM's financial struggles are not isolated, as biotech sector averages include negative ROE and profit margins
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial distress and poor fundamental strength
Operating margin of -1307.60% and gross margin of 0.00% indicate no viable path to profitability in the near term
Revenue growth is sharply negative at -32.00% YoY, reversing prior growth trends and signaling weakening commercial momentum
Insiders have been net sellers with $3.19M in sales over the last 6 months and zero buy transactions, suggesting lack of confidence
Extremely high valuation metrics — Price/Sales of 57.50 and negative Forward P/E of -6.85 — imply speculative pricing with no earnings support
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BEAM against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning BEAM from our newsroom.
Newest → oldest
No matching news yet.